{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000923","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.846715+00:00","generated_at":"2026-05-24T04:32:43.260096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M","bullets":["Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).","FY product revenue $9.2M (flat YoY); tests ~24,305 (+1.3%); AUP $378 (-1.0%); gross margin 59.7% (+2.2 ppts).","Operating expenses Q4 $4.9M (-8% YoY); FY $21.8M (-10% YoY).","Cash ~$3.7M as of Mar 27, 2025; pending $1.5M ARPA-H milestone; raised $5.75M via convertible notes and ATM.","New CEO Mike Buhle appointed; ARPA-H $10M award milestone; Ellen Beausang added to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000923","json":"https://secwatch.observer/filing/0001641172-25-000923.json","markdown":"https://secwatch.observer/filing/0001641172-25-000923.md","text":"https://secwatch.observer/filing/0001641172-25-000923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000164117225000923/0001641172-25-000923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000164117225000923/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:32:43.260096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}